

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

**COMPLETION OF THE MAJOR AND CONNECTED TRANSACTION  
IN RELATION TO THE DISPOSAL OF TARGET EQUITY IN  
SUNSHINE LAKE PHARMA**

Reference is made to the announcement of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 23 December 2022 (the “**Announcement**”) and the circular of the Company dated 10 March 2023 (the “**Circular**”) in relation to the entering into of the Equity Transfer Agreement between the Company, Shenzhen HEC Industrial and Sunshine Lake Pharma, pursuant to which, the Company agreed to transfer and Shenzhen HEC Industrial agreed to acquire 9.9134% of the Target Equity of Sunshine Lake Pharma held by the Company at a consideration of RMB2,312,319,650. Unless otherwise specified, capitalised terms herein shall have the same meanings as defined in the Announcement and the Circular.

The Board is pleased to announce that all conditions precedents under the Equity Transfer Agreement have been fulfilled on 27 June 2023, the Company has received the Consideration under the Equity Transfer Agreement in full and completion has taken place on 27 June 2023. Upon Completion, the Company will cease to hold any interest in Sunshine Lake Pharma.

On behalf of the Board

**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**TANG Xinfa**

*Chairman*

Hubei, the People's Republic of China  
27 June 2023

*As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa as non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.*